Effects of semaglutide on body weight in clozapine-treated people with schizophrenia and obesity: study protocol for a placebo-controlled, randomised multicentre trial (COaST)

BACKGROUND: People with schizophrenia die almost 20 years earlier than the general population, most commonly from avertable cardiometabolic disease. Existing pharmacological weight-loss agents including metformin have limited efficacy. Recently available glucagon-like peptide (GLP-1) receptor agonis...

Descripción completa

Detalles Bibliográficos
Autores principales: Siskind, Dan, Baker, Andrea, Russell, Anthony, Warren, Nicola, Robinson, Gail, Parker, Stephen, Medland, Sarah, Kisely, Steve, Hager, Tineka, Arnautovska, Urska
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375878/
http://dx.doi.org/10.1192/bjo.2023.532

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375878/
http://dx.doi.org/10.1192/bjo.2023.532

Ejemplares similares